Trial Profile
A Study Assessing Safety and Efficacy of Denosumab in Daily Practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Jul 2017
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Fracture; Metabolic bone diseases; Osteopetrosis; Rheumatic disorders
- Focus Adverse reactions; Therapeutic Use
- 06 Jul 2017 New trial record
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism.